Trial Profile
PERSEUS1: Phase II Trial of the Immune Checkpoint Inhibitor Pembrolizumab for Patients Suffering From Metastatic Prostate Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PERSEUS-1
- 27 Jan 2024 Results of stage 1 (n=25) presented at the 2024 Genitourinary Cancers Symposium.
- 21 Dec 2018 Status changed from not yet recruiting to recruiting.
- 15 Nov 2018 Planned initiation date changed from 8 Oct 2018 to 30 Nov 2018.